Literature DB >> 9032385

Phenotypically Vif- human immunodeficiency virus type 1 is produced by chronically infected restrictive cells.

M Bouyac1, F Rey, M Nascimbeni, M Courcoul, J Sire, D Blanc, F Clavel, R Vigne, B Spire.   

Abstract

The permissivity of CD4+ transformed T cells for the replication of human immunodeficiency virus type 1 (HIV-1) vif mutants varies widely between different cell lines. Mutant vif-negative viruses propagate normally in permissive CD4+ cell lines but are unable to establish a productive infection in restrictive cell lines such as H9. As a consequence, elucidation of the function of Vif has been considerably hampered by the inherent difficulty in obtaining a stable source of authentically replication-defective vif-negative viral particles produced by restrictive cells. vif-negative, vpr-negative HIV-1 strain NDK stock, produced by the permissive SupT1 cell line, was used to infect restrictive H9 cells. By using a high multiplicity, infection of H9 cells was achieved, leading to persistent production of viral particles displaying a dramatically reduced infectious virus titer when measured in a single-cycle infectivity assay. Although these viral particles were unable to further propagate in H9 cells, they could replicate normally in CEM and SupT1 cells. Comparison of unprocessed and processed Gag proteins in the persistently produced vif-negative viral particles revealed no defect in the processing of polypeptide precursors, with no inversion of the Pr55gag/p24 ratio. In addition, there was no defect in Env incorporation for the vif-negative viral particles. Despite their apparently normal protein content, these particles were morphologically abnormal when examined by transmission electron microscopy, displaying a previously described abnormally condensed nucleoid. Chronically infected restrictive cell lines producing stable levels of phenotypically vif-negative HIV-1 particles could prove particularly useful in further studies on the function of Vif in the virus life cycle.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9032385      PMCID: PMC191358     

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  22 in total

1.  HIV-1 reverse transcription. A termination step at the center of the genome.

Authors:  P Charneau; G Mirambeau; P Roux; S Paulous; H Buc; F Clavel
Journal:  J Mol Biol       Date:  1994-09-02       Impact factor: 5.469

2.  Human immunodeficiency virus type 1 Vif- mutant particles from restrictive cells: role of Vif in correct particle assembly and infectivity.

Authors:  A M Borman; C Quillent; P Charneau; C Dauguet; F Clavel
Journal:  J Virol       Date:  1995-04       Impact factor: 5.103

3.  Role of vif during packing of the core of HIV-1.

Authors:  S Höglund; A Ohagen; K Lawrence; D Gabuzda
Journal:  Virology       Date:  1994-06       Impact factor: 3.616

4.  Transcomplementation of VIF- HIV-1 mutants in CEM cells suggests that VIF affects late steps of the viral life cycle.

Authors:  D Blanc; C Patience; T F Schulz; R Weiss; B Spire
Journal:  Virology       Date:  1993-03       Impact factor: 3.616

5.  Cell-dependent requirement of human immunodeficiency virus type 1 Vif protein for maturation of virus particles.

Authors:  H Sakai; R Shibata; J Sakuragi; S Sakuragi; M Kawamura; A Adachi
Journal:  J Virol       Date:  1993-03       Impact factor: 5.103

6.  Aberrant Gag protein composition of a human immunodeficiency virus type 1 vif mutant produced in primary lymphocytes.

Authors:  M Simm; M Shahabuddin; W Chao; J S Allan; D J Volsky
Journal:  J Virol       Date:  1995-07       Impact factor: 5.103

7.  Subcellular localization of the Vif protein of human immunodeficiency virus type 1.

Authors:  J Goncalves; P Jallepalli; D H Gabuzda
Journal:  J Virol       Date:  1994-02       Impact factor: 5.103

8.  The human immunodeficiency virus type 1 vpr gene prevents cell proliferation during chronic infection.

Authors:  M E Rogel; L I Wu; M Emerman
Journal:  J Virol       Date:  1995-02       Impact factor: 5.103

9.  Efficiency of viral DNA synthesis during infection of permissive and nonpermissive cells with vif-negative human immunodeficiency virus type 1.

Authors:  P Sova; D J Volsky
Journal:  J Virol       Date:  1993-10       Impact factor: 5.103

10.  Peripheral blood mononuclear cells produce normal amounts of defective Vif- human immunodeficiency virus type 1 particles which are restricted for the preretrotranscription steps.

Authors:  M Courcoul; C Patience; F Rey; D Blanc; A Harmache; J Sire; R Vigne; B Spire
Journal:  J Virol       Date:  1995-04       Impact factor: 5.103

View more
  25 in total

1.  Vif is largely absent from human immunodeficiency virus type 1 mature virions and associates mainly with viral particles containing unprocessed gag.

Authors:  P Sova; D J Volsky; L Wang; W Chao
Journal:  J Virol       Date:  2001-06       Impact factor: 5.103

2.  Inhibition of tRNA₃(Lys)-primed reverse transcription by human APOBEC3G during human immunodeficiency virus type 1 replication.

Authors:  Fei Guo; Shan Cen; Meijuan Niu; Jenan Saadatmand; Lawrence Kleiman
Journal:  J Virol       Date:  2006-09-13       Impact factor: 5.103

3.  Feline immunodeficiency virus Vif localizes to the nucleus.

Authors:  U Chatterji; C K Grant; J H Elder
Journal:  J Virol       Date:  2000-03       Impact factor: 5.103

4.  Partial rescue of the Vif-negative phenotype of mutant human immunodeficiency virus type 1 strains from nonpermissive cells by intravirion reverse transcription.

Authors:  G Dornadula; S Yang; R J Pomerantz; H Zhang
Journal:  J Virol       Date:  2000-03       Impact factor: 5.103

5.  The regulation of primate immunodeficiency virus infectivity by Vif is cell species restricted: a role for Vif in determining virus host range and cross-species transmission.

Authors:  J H Simon; D L Miller; R A Fouchier; M A Soares; K W Peden; M H Malim
Journal:  EMBO J       Date:  1998-08-10       Impact factor: 11.598

6.  Human immunodeficiency virus type 1 Vif protein binds to the Pr55Gag precursor.

Authors:  M Bouyac; M Courcoul; G Bertoia; Y Baudat; D Gabuzda; D Blanc; N Chazal; P Boulanger; J Sire; R Vigne; B Spire
Journal:  J Virol       Date:  1997-12       Impact factor: 5.103

7.  Human immunodeficiency virus type 1 Vif protein is packaged into the nucleoprotein complex through an interaction with viral genomic RNA.

Authors:  M A Khan; C Aberham; S Kao; H Akari; R Gorelick; S Bour; K Strebel
Journal:  J Virol       Date:  2001-08       Impact factor: 5.103

8.  Identification of a functionally important amino acid residue near to the amino-terminus of the human immunodeficiency virus type 1 Vif protein.

Authors:  M Boyce; P Willingmann; M McCrae
Journal:  Virus Genes       Date:  1999       Impact factor: 2.332

9.  The human immunodeficiency virus type 1 Vif protein reduces intracellular expression and inhibits packaging of APOBEC3G (CEM15), a cellular inhibitor of virus infectivity.

Authors:  Sandra Kao; Mohammad A Khan; Eri Miyagi; Ron Plishka; Alicia Buckler-White; Klaus Strebel
Journal:  J Virol       Date:  2003-11       Impact factor: 5.103

10.  Highly purified human immunodeficiency virus type 1 reveals a virtual absence of Vif in virions.

Authors:  M Dettenhofer; X F Yu
Journal:  J Virol       Date:  1999-02       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.